Zhejiang Wolwo Bio-Pharmaceutical (SHE:300357) unit Zhejiang Stem Cell obtained acceptance from China's drug regulator for the clinical trial application for its human umbilical cord mesenchymal Stem cells type II injection.
The stem cell therapy targets sepsis and septic shock, according to a Wednesday filing with the Shenzhen bourse.
Shares of the drug company closed 1% higher Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments